Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070296
Filing Date
2025-05-13
Accepted
2025-05-13 16:05:31
Documents
68
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q stok-20250331.htm   iXBRL 10-Q 2148991
2 EX-10.1 stok-ex10_1.htm EX-10.1 41281
3 EX-10.2 stok-ex10_2.htm EX-10.2 1209629
4 EX-31.1 stok-ex31_1.htm EX-31.1 17882
5 EX-31.2 stok-ex31_2.htm EX-31.2 17687
6 EX-32.1 stok-ex32_1.htm EX-32.1 9437
7 EX-32.2 stok-ex32_2.htm EX-32.2 10490
  Complete submission text file 0000950170-25-070296.txt   9145419

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT stok-20250331.xsd EX-101.SCH 902182
70 EXTRACTED XBRL INSTANCE DOCUMENT stok-20250331_htm.xml XML 1312985
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

EIN.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38938 | Film No.: 25939964
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)